Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease

Observational study of ctDNA to predict ovarian-cancer recurrence by assessing residual disease (estimated n=45). ClinicalTrials.gov API v2 on 13 Nov 2026: status UNKNOWN, start 2022-10-07, primary completion 2024-12-30, last update 2024-02-01. No peer-reviewed primary results paper was identified in this review.

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)